# Elevance Health, Inc.: financial statements, quarterly

ELV · NYSE · CIK 1156039 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/elv.md) · [Financials](/companies/elv/financials.md) · [Filings](/companies/elv/filings.md) · [Insiders](/companies/elv/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/elv/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [42.6 d](/filings/0001156039-26-000013.md) | [42.6](/filings/0001156039-25-000057.md) | [43.9](/filings/0001156039-25-000114.md) | [45.1](/filings/0001156039-25-000136.md) | [45.4 d](/filings/0001156039-26-000013.md) | [48.9](/filings/0001156039-26-000043.md) | [49.8](/filings/0001156039-26-000060.md) | [50.7](/filings/0001156039-26-000071.md) | [49.7 d](/filings/0001156039-26-000013.md) | [50.2](/filings/0001156039-26-000043.md) | [50.5](/filings/0001156039-26-000060.md) | [51.4](/filings/0001156039-26-000071.md) |
| Cost of revenue | $bn | [4.8 d](/filings/0001156039-26-000013.md) | [3.8](/filings/0001156039-25-000057.md) | [4.8](/filings/0001156039-25-000114.md) | [5.1](/filings/0001156039-25-000136.md) | [6.0 d](/filings/0001156039-26-000013.md) | [5.0](/filings/0001156039-26-000043.md) | [5.3](/filings/0001156039-26-000060.md) | [5.4](/filings/0001156039-26-000071.md) | [5.5 d](/filings/0001156039-26-000013.md) | [5.5](/filings/0001156039-26-000043.md) | [5.5](/filings/0001156039-26-000060.md) | [5.6](/filings/0001156039-26-000071.md) |
| Selling, general and administrative | $bn | [5.0 d](/filings/0001156039-26-000013.md) | [4.9](/filings/0001156039-25-000057.md) | [5.1](/filings/0001156039-25-000114.md) | [5.3](/filings/0001156039-25-000136.md) | [4.8 d](/filings/0001156039-26-000013.md) | [5.3](/filings/0001156039-26-000043.md) | [5.0](/filings/0001156039-26-000060.md) | [5.3](/filings/0001156039-26-000071.md) | [5.4 d](/filings/0001156039-26-000013.md) | [6.3](/filings/0001156039-26-000043.md) | [5.5](/filings/0001156039-26-000060.md) | [5.8](/filings/0001156039-26-000071.md) |
| Operating income | $bn | [1.3 d](/filings/0001156039-26-000013.md) | [3.0](/filings/0001156039-25-000057.md) | [2.8](/filings/0001156039-25-000114.md) | [1.4](/filings/0001156039-25-000136.md) | [0.7 d](/filings/0001156039-26-000013.md) | [3.2](/filings/0001156039-26-000043.md) | [2.4](/filings/0001156039-26-000060.md) | [1.3](/filings/0001156039-26-000071.md) | [0.3 d](/filings/0001156039-26-000013.md) | [2.1](/filings/0001156039-26-000043.md) | [1.8](/filings/0001156039-26-000060.md) | [1.3](/filings/0001156039-26-000071.md) |
| Interest expense | $bn | [0.3 d](/filings/0001156039-24-000015.md) | [0.3](/filings/0001156039-24-000066.md) | [0.3](/filings/0001156039-24-000104.md) | [0.3](/filings/0001156039-24-000122.md) | [0.3 d](/filings/0001156039-26-000013.md) | [0.3](/filings/0001156039-26-000043.md) | [0.3](/filings/0001156039-26-000060.md) | [0.4](/filings/0001156039-26-000071.md) | [0.4 d](/filings/0001156039-26-000013.md) | [0.4](/filings/0001156039-26-000043.md) | [0.4](/filings/0001156039-26-000060.md) | [0.4](/filings/0001156039-26-000071.md) |
| Income tax | $bn | [0.2 d](/filings/0001156039-26-000013.md) | [0.7](/filings/0001156039-25-000057.md) | [0.7](/filings/0001156039-25-000114.md) | [0.4](/filings/0001156039-25-000136.md) | [0.2 d](/filings/0001156039-26-000013.md) | [0.6](/filings/0001156039-26-000043.md) | [0.5](/filings/0001156039-26-000060.md) | [0.2](/filings/0001156039-26-000071.md) | [(0.3) d](/filings/0001156039-26-000013.md) | [0.5](/filings/0001156039-26-000043.md) | [0.5](/filings/0001156039-26-000060.md) | [0.5](/filings/0001156039-26-000071.md) |
| Net income | $bn | [0.9 d](/filings/0001156039-26-000013.md) | [2.2](/filings/0001156039-25-000057.md) | [2.3](/filings/0001156039-25-000114.md) | [1.0](/filings/0001156039-25-000136.md) | [0.4 d](/filings/0001156039-26-000013.md) | [2.2](/filings/0001156039-26-000043.md) | [1.7](/filings/0001156039-26-000060.md) | [1.2](/filings/0001156039-26-000071.md) | [0.5 d](/filings/0001156039-26-000013.md) | [1.8](/filings/0001156039-26-000043.md) | [1.5](/filings/0001156039-26-000060.md) | [1.4](/filings/0001156039-26-000071.md) |
| Diluted EPS | $ per share | not reported | [9.59](/filings/0001156039-25-000057.md) | [9.85](/filings/0001156039-25-000114.md) | [4.36](/filings/0001156039-25-000136.md) | not reported | [9.61](/filings/0001156039-26-000043.md) | [7.72](/filings/0001156039-26-000060.md) | [5.32](/filings/0001156039-26-000071.md) | not reported | [8.00](/filings/0001156039-26-000043.md) | [6.71](/filings/0001156039-26-000060.md) | [6.27](/filings/0001156039-26-000071.md) |
| Basic EPS | $ per share | not reported | [9.65](/filings/0001156039-25-000057.md) | [9.91](/filings/0001156039-25-000114.md) | [4.38](/filings/0001156039-25-000136.md) | not reported | [9.64](/filings/0001156039-26-000043.md) | [7.74](/filings/0001156039-26-000060.md) | [5.32](/filings/0001156039-26-000071.md) | not reported | [8.03](/filings/0001156039-26-000043.md) | [6.74](/filings/0001156039-26-000060.md) | [6.30](/filings/0001156039-26-000071.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [6.5](/filings/0001156039-25-000010.md) | [6.2](/filings/0001156039-24-000066.md) | [6.5](/filings/0001156039-24-000104.md) | [7.9](/filings/0001156039-24-000122.md) | [8.3](/filings/0001156039-26-000013.md) | [7.5](/filings/0001156039-25-000057.md) | [8.6](/filings/0001156039-25-000114.md) | [8.7](/filings/0001156039-25-000136.md) | [9.5](/filings/0001156039-26-000071.md) | [9.7](/filings/0001156039-26-000043.md) | [10.2](/filings/0001156039-26-000060.md) | [10.3](/filings/0001156039-26-000071.md) |
| Current assets | $bn | [60.0](/filings/0001156039-25-000010.md) | [60.9](/filings/0001156039-24-000066.md) | [62.3](/filings/0001156039-24-000104.md) | [62.8](/filings/0001156039-24-000122.md) | [58.9](/filings/0001156039-26-000013.md) | [61.1](/filings/0001156039-25-000057.md) | [63.3](/filings/0001156039-25-000114.md) | [63.8](/filings/0001156039-25-000136.md) | [63.0](/filings/0001156039-26-000071.md) | [67.0](/filings/0001156039-26-000043.md) | [67.2](/filings/0001156039-26-000060.md) | [68.5](/filings/0001156039-26-000071.md) |
| Total assets | $bn | [109](/filings/0001156039-25-000010.md) | [112](/filings/0001156039-24-000066.md) | [113](/filings/0001156039-24-000104.md) | [117](/filings/0001156039-24-000122.md) | [117](/filings/0001156039-26-000013.md) | [120](/filings/0001156039-25-000057.md) | [122](/filings/0001156039-25-000114.md) | [123](/filings/0001156039-25-000136.md) | [121](/filings/0001156039-26-000071.md) | [126](/filings/0001156039-26-000043.md) | [126](/filings/0001156039-26-000060.md) | [128](/filings/0001156039-26-000071.md) |
| Current liabilities | $bn | [41.8](/filings/0001156039-25-000010.md) | [44.3](/filings/0001156039-24-000066.md) | [41.8](/filings/0001156039-24-000104.md) | [42.0](/filings/0001156039-24-000122.md) | [40.6](/filings/0001156039-26-000013.md) | [42.7](/filings/0001156039-25-000057.md) | [43.8](/filings/0001156039-25-000114.md) | [40.9](/filings/0001156039-25-000136.md) | [41.0](/filings/0001156039-26-000071.md) | [45.3](/filings/0001156039-26-000043.md) | [44.3](/filings/0001156039-26-000060.md) | [46.7](/filings/0001156039-26-000071.md) |
| Total liabilities | $bn | [69.5](/filings/0001156039-25-000010.md) | [71.2](/filings/0001156039-24-000066.md) | [70.7](/filings/0001156039-24-000104.md) | [72.7](/filings/0001156039-24-000122.md) | [75.5](/filings/0001156039-26-000013.md) | [77.1](/filings/0001156039-25-000057.md) | [78.1](/filings/0001156039-25-000114.md) | [78.7](/filings/0001156039-25-000136.md) | [77.5](/filings/0001156039-26-000071.md) | [81.8](/filings/0001156039-26-000043.md) | [81.4](/filings/0001156039-26-000060.md) | [83.0](/filings/0001156039-26-000071.md) |
| Long-term debt | $bn | [23.2](/filings/0001156039-25-000010.md) | [22.0](/filings/0001156039-24-000066.md) | [24.6](/filings/0001156039-24-000104.md) | [24.7](/filings/0001156039-24-000122.md) | [29.2](/filings/0001156039-26-000013.md) | [28.1](/filings/0001156039-25-000057.md) | [28.2](/filings/0001156039-25-000114.md) | [31.2](/filings/0001156039-25-000136.md) | [30.8](/filings/0001156039-26-000071.md) | [30.8](/filings/0001156039-26-000043.md) | [30.7](/filings/0001156039-26-000060.md) | [30.4](/filings/0001156039-26-000071.md) |
| Current portion of debt | $bn | [1.6](/filings/0001156039-25-000010.md) | [2.9](/filings/0001156039-24-000066.md) | [2.9](/filings/0001156039-24-000104.md) | [2.1](/filings/0001156039-24-000122.md) | [1.6](/filings/0001156039-26-000013.md) | [1.6](/filings/0001156039-25-000057.md) | [1.6](/filings/0001156039-25-000114.md) | [0.7](/filings/0001156039-25-000136.md) | [1.1](/filings/0001156039-26-000071.md) | [0.4](/filings/0001156039-26-000043.md) | [0.4](/filings/0001156039-26-000060.md) | [0.4](/filings/0001156039-26-000071.md) |
| Short-term borrowings | $bn | [0.2](/filings/0001156039-25-000010.md) | [1.6](/filings/0001156039-24-000066.md) | [0.2](/filings/0001156039-24-000104.md) | [0.4](/filings/0001156039-24-000122.md) | [0.4](/filings/0001156039-26-000013.md) | [0.3](/filings/0001156039-25-000057.md) | [0.4](/filings/0001156039-25-000114.md) | [0.2](/filings/0001156039-25-000136.md) | [0.2](/filings/0001156039-26-000071.md) | [0.7](/filings/0001156039-26-000043.md) | [0.0](/filings/0001156039-26-000060.md) | [0.0](/filings/0001156039-26-000071.md) |
| Shareholders' equity | $bn | [39.3](/filings/0001156039-25-000010.md) | [40.6](/filings/0001156039-24-000066.md) | [42.2](/filings/0001156039-24-000104.md) | [43.8](/filings/0001156039-24-000122.md) | [41.3](/filings/0001156039-26-000013.md) | [42.5](/filings/0001156039-25-000057.md) | [43.7](/filings/0001156039-25-000114.md) | [44.0](/filings/0001156039-25-000136.md) | [43.9](/filings/0001156039-26-000071.md) | [43.9](/filings/0001156039-26-000043.md) | [44.9](/filings/0001156039-26-000060.md) | [44.7](/filings/0001156039-26-000071.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(2,971) d](/filings/0001156039-26-000013.md) | [1,978](/filings/0001156039-25-000057.md) | [447 d](/filings/0001156039-25-000114.md) | [2,677 d](/filings/0001156039-25-000136.md) | [706 d](/filings/0001156039-26-000013.md) | [1,017](/filings/0001156039-26-000043.md) | [2,054 d](/filings/0001156039-26-000060.md) | [1,135 d](/filings/0001156039-26-000071.md) | [84.0 d](/filings/0001156039-26-000013.md) | [4,332](/filings/0001156039-26-000043.md) | [1,913 d](/filings/0001156039-26-000060.md) | [1,267 d](/filings/0001156039-26-000071.md) |
| Capital expenditure | $m | [326 d](/filings/0001156039-26-000013.md) | [279](/filings/0001156039-25-000057.md) | [323 d](/filings/0001156039-25-000114.md) | [332 d](/filings/0001156039-25-000136.md) | [322 d](/filings/0001156039-26-000013.md) | [196](/filings/0001156039-26-000043.md) | [267 d](/filings/0001156039-26-000060.md) | [360 d](/filings/0001156039-26-000071.md) | [293 d](/filings/0001156039-26-000013.md) | [235](/filings/0001156039-26-000043.md) | [287 d](/filings/0001156039-26-000060.md) | [267 d](/filings/0001156039-26-000071.md) |
| Dividends paid | $m | [346](/filings/0001156039-25-000010.md) | [379](/filings/0001156039-26-000013.md) | [378](/filings/0001156039-26-000013.md) | [386](/filings/0001156039-26-000043.md) | [373](/filings/0001156039-26-000013.md) | [386](/filings/0001156039-26-000071.md) | [385](/filings/0001156039-26-000071.md) | [381](/filings/0001156039-26-000071.md) | [377](/filings/0001156039-26-000013.md) | [376](/filings/0001156039-26-000071.md) | [373](/filings/0001156039-26-000071.md) | [373](/filings/0001156039-26-000071.md) |
| Share repurchases | $m | [928 d](/filings/0001156039-26-000013.md) | [566](/filings/0001156039-25-000057.md) | [463 d](/filings/0001156039-25-000114.md) | [60.0 d](/filings/0001156039-25-000136.md) | [1,811 d](/filings/0001156039-26-000013.md) | [880](/filings/0001156039-26-000043.md) | [378 d](/filings/0001156039-26-000060.md) | [876 d](/filings/0001156039-26-000071.md) | [471 d](/filings/0001156039-26-000013.md) | [1,124](/filings/0001156039-26-000043.md) | [234 d](/filings/0001156039-26-000060.md) | [330 d](/filings/0001156039-26-000071.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [240](/filings/0001156039-24-000066.md) | [238](/filings/0001156039-24-000104.md) | [237](/filings/0001156039-24-000122.md) | [234](/filings/0001156039-25-000057.md) | [233](/filings/0001156039-25-000114.md) | [233](/filings/0001156039-25-000136.md) | [227](/filings/0001156039-26-000043.md) | [226](/filings/0001156039-26-000060.md) | [224](/filings/0001156039-26-000071.md) | [220](/filings/0001156039-26-000043.md) | [218](/filings/0001156039-26-000060.md) | [218](/filings/0001156039-26-000071.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 216,055,891 at 2026-10-15, from the cover of the [10-Q filed 2026-10-21](/filings/0001156039-26-000071.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.